204 related articles for article (PubMed ID: 22986484)
1. Correlation between protective immunity to α-synuclein aggregates, oxidative stress and inflammation.
Gruden MA; Yanamandra K; Kucheryanu VG; Bocharova OR; Sherstnev VV; Morozova-Roche LA; Sewell RD
Neuroimmunomodulation; 2012; 19(6):334-42. PubMed ID: 22986484
[TBL] [Abstract][Full Text] [Related]
2. Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression.
Gruden MA; Sewell RD; Yanamandra K; Davidova TV; Kucheryanu VG; Bocharov EV; Bocharova OA; Polyschuk VV; Sherstnev VV; Morozova-Roche LA
J Neuroimmunol; 2011 Apr; 233(1-2):221-7. PubMed ID: 21239064
[TBL] [Abstract][Full Text] [Related]
3. Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation.
Zhang QS; Heng Y; Yuan YH; Chen NH
Toxicol Lett; 2017 Jan; 265():30-37. PubMed ID: 27865851
[TBL] [Abstract][Full Text] [Related]
4. Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease.
Gustot A; Gallea JI; Sarroukh R; Celej MS; Ruysschaert JM; Raussens V
Biochem J; 2015 Nov; 471(3):323-33. PubMed ID: 26272943
[TBL] [Abstract][Full Text] [Related]
5. α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients.
Yanamandra K; Gruden MA; Casaite V; Meskys R; Forsgren L; Morozova-Roche LA
PLoS One; 2011 Apr; 6(4):e18513. PubMed ID: 21541339
[TBL] [Abstract][Full Text] [Related]
6. Nasal inoculation with α-synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine.
Gruden MA; Davidova TV; Yanamandra K; Kucheryanu VG; Morozova-Roche LA; Sherstnev VV; Sewell RD
Behav Brain Res; 2013 Apr; 243():205-12. PubMed ID: 23333843
[TBL] [Abstract][Full Text] [Related]
7. Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease.
Besong-Agbo D; Wolf E; Jessen F; Oechsner M; Hametner E; Poewe W; Reindl M; Oertel WH; Noelker C; Bacher M; Dodel R
Neurology; 2013 Jan; 80(2):169-75. PubMed ID: 23255825
[TBL] [Abstract][Full Text] [Related]
8. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
Lev N; Melamed E; Offen D
Neurosci Lett; 2006 May; 399(1-2):27-32. PubMed ID: 16584840
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.
Shannon KM; Keshavarzian A; Mutlu E; Dodiya HB; Daian D; Jaglin JA; Kordower JH
Mov Disord; 2012 May; 27(6):709-15. PubMed ID: 21766334
[TBL] [Abstract][Full Text] [Related]
10. Colonic inflammation in Parkinson's disease.
Devos D; Lebouvier T; Lardeux B; Biraud M; Rouaud T; Pouclet H; Coron E; Bruley des Varannes S; Naveilhan P; Nguyen JM; Neunlist M; Derkinderen P
Neurobiol Dis; 2013 Feb; 50():42-8. PubMed ID: 23017648
[TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
12. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
13. Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies.
Schildknecht S; Gerding HR; Karreman C; Drescher M; Lashuel HA; Outeiro TF; Di Monte DA; Leist M
J Neurochem; 2013 May; 125(4):491-511. PubMed ID: 23452040
[TBL] [Abstract][Full Text] [Related]
14. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.
Zhang W; Wang T; Pei Z; Miller DS; Wu X; Block ML; Wilson B; Zhang W; Zhou Y; Hong JS; Zhang J
FASEB J; 2005 Apr; 19(6):533-42. PubMed ID: 15791003
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies.
Brudek T; Winge K; Folke J; Christensen S; Fog K; Pakkenberg B; Pedersen LØ
Mol Neurodegener; 2017 Jun; 12(1):44. PubMed ID: 28592329
[TBL] [Abstract][Full Text] [Related]
16. Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy.
Sultana Z; Paleologou KE; Al-Mansoori KM; Ardah MT; Singh N; Usmani S; Jiao H; Martin FL; Bharath MM; Vali S; El-Agnaf OM
Neuroscience; 2011 Dec; 199():303-17. PubMed ID: 22056602
[TBL] [Abstract][Full Text] [Related]
17. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
18. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
[TBL] [Abstract][Full Text] [Related]
19. Selective detection, quantification, and subcellular location of alpha-synuclein aggregates with a protein aggregate filtration assay.
Kramer ML; Behrens C; Schulz-Schaeffer WJ
Biotechniques; 2008 Mar; 44(3):403-11. PubMed ID: 18361794
[TBL] [Abstract][Full Text] [Related]
20. Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein.
Kobayashi M; Kim J; Kobayashi N; Han S; Nakamura C; Ikebukuro K; Sode K
Biochem Biophys Res Commun; 2006 Oct; 349(3):1139-44. PubMed ID: 16962995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
